Board of Directors
The Board's composition includes independent directors. Director roster and term details are published in GlycoNex's statutory filings via MOPS.
Investor Relations
Investor Relations
GlycoNex, Inc. is a clinical-stage biopharmaceutical company listed on Taiwan's over-the-counter (OTC) market under ticker 4168, traded on the Taipei Exchange (TPEx) since 2012. Statutory filings are published through the Market Observation Post System (MOPS); this page summarizes financial performance and governance.
Ticker
TWO:4168
Market
Taipei Exchange (OTC)
Listed
2012
FY2025 Revenue
NTD 37.9M
02 — Financial Snapshot
Three-Year Operating Trend
Figures are drawn from public TWSE/MOPS filings.
| Fiscal year | Revenue | R&D expense |
|---|---|---|
| FY 2023 | NTD 2.5M ~USD 85K | NTD 210.4M |
| FY 2024 | NTD 14.7M ~USD 490K | NTD 204.6M |
| FY 2025 | NTD 37.9M ~USD 1.26M | NTD 222.7M |
Revenue grew more than 14× from 2023 to 2025 (+478% in 2024, +158% in 2025), while R&D investment was sustained above NTD 200M per year.
- FY2025 — Net loss after tax NTD 235.2M ~USD 7.84M
- Total assets (period end) NTD 1,554.2M ~USD 51.8M
- Equity attributable to owners of the parent NTD 982.3M ~USD 32.7M
- Revenue streams Licensing income · technology service income · contract antibody R&D service income
In 2025, GlycoNex completed its fourth domestic secured convertible bond issuance and a cash capital increase, primarily to fund GNX1021 preclinical and Phase 1 clinical development.
USD approximations shown at NTD 30 = USD 1 for reference only. Net loss is typical for a clinical-stage biopharmaceutical company in active development.
03 — Official Disclosures
Statutory Filings & Market Data
GlycoNex's statutory disclosures — including material information, monthly revenue, and financial statements — are published in full through official channels:
04 — Corporate Governance
Board, Committees & Oversight Structure
Audit & Remuneration Committees
An Audit Committee and a Remuneration Committee operate under the Board, providing oversight over financial reporting, controls, and compensation.
Corporate Governance Evaluation
GlycoNex participates in the annual corporate governance evaluation conducted for TPEx and TWSE listed companies.
Financial & Administrative Management Division
The Financial and Administrative Management Division oversees corporate governance, investor relations, and compliance functions for the company.
05 — Investor Materials & Sustainability